Elcys Patent Expiration

ELCYS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11510942 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10478453 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10583155 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10653719 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10918662 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10905713 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10905714 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11684636 EXELA PHARMA Stable, highly pure l-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10933089 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11826383 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11679125 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11648262 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US10912795 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11642370 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)

US11510941 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(14 years from now)



Elcys is a drug owned by Exela Pharma Sciences Llc. It is used for parenteral nutrition support in patients. Elcys uses Cysteine Hydrochloride as an active ingredient. Elcys was launched by Exela Pharma in 2019. It is is available in solution form for intravenous use. Its generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 15, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 April, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition

Dosage: SOLUTION

How can I launch a generic of ELCYS before it's drug patent expiration?
More Information on Dosage

ELCYS family patents

Family Patents